Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 07 Aug 2024

EMT-related gene classifications predict the prognosis, immune infiltration, and therapeutic response of osteosarcoma

in Pharmacology of Anti-Cancer Drugs

Meng-Pan Li
Si-Ping Long
Wen-Cai Liu
Kun Long
Xing-Hua Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1419040

1,825 views
1 citation

Original Research

Published on 07 Aug 2024

Schisandrin C enhances type I IFN response activation to reduce tumor growth and sensitize chemotherapy through antitumor immunity

in Pharmacology of Anti-Cancer Drugs

Huijie Yang
Xiaoyan Zhan
Jia Zhao
Wei Shi
Tingting Liu
Ziying Wei
Hui Li
Xiaorong Hou
Wenqing Mu
Yuanyuan Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1369563

2,192 views
6 citations

Review

Published on 07 Aug 2024

Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma

in Pharmacology of Anti-Cancer Drugs

Yanxin Sun
Wei Jiang
Ruiheng Duan
Lianyue Guan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1432603

2,185 views
1 citation

Original Research

Published on 06 Aug 2024

Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study

in Pharmacology of Anti-Cancer Drugs

Yilong Lin
Yue Zhang
Songsong Wang
Lin Cao
Ruidan Zhao
Xilai Ma
Qiaolu Yang
Liyi Zhang
Qingmo Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1443045

4,379 views
5 citations

Original Research

Published on 05 Aug 2024

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents

in Pharmacology of Anti-Cancer Drugs

Xuanhong Jin
Yang Pan
Cheng Cheng
Hangchen Shen
Chongya Zhai
Kailai Yin
Xinyu Zhu
Hongming Pan
Liangkun You

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391972

1,748 views
2 citations

Review

Published on 05 Aug 2024

Chitosan-based biomaterial delivery strategies for hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Xianling Wang
Yan Yang
Shuang Zhao
Di Wu
Le Li
Zhifeng Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1446030

1,709 views
2 citations

Review

Published on 05 Aug 2024

Anti-tumor effect and hepatotoxicity mechanisms of psoralen

in Pharmacology of Anti-Cancer Drugs

Dandan Meng
Yanling Dong
Qingxin Shang
Ziyuan Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1442700

2,850 views
2 citations

Correction

Published on 05 Aug 2024

Corrigendum: Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells

in Pharmacology of Anti-Cancer Drugs

Wei Huang
Xia Yuan
Ting Sun
Shujie Fan
Jun Wang
Quan Zhou
Wei Guo
Fuxiang Ran
Zemei Ge
Huayu Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1418274

849 views

Systematic Review

Published on 05 Aug 2024

Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Xin Guan
Mengyuan Li
Xinyue Ji
Yufei Wang
Lei Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1369420

3,234 views

Review

Published on 05 Aug 2024

Unveiling the multifaceted roles of microRNAs in extracellular vesicles derived from mesenchymal stem cells: implications in tumor progression and therapeutic interventions

in Pharmacology of Anti-Cancer Drugs

Sujia Hu
Chang Zhang
Qianhui Ma
Minghe Li
Xiao Yu
Haiying Zhang
Shuang Lv
Yingai Shi
Xu He

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1438177

1,794 views
1 citation

Review

Published on 02 Aug 2024

Global research development of chondrosarcoma from 2003 to 2022: a bibliometric analysis

in Pharmacology of Anti-Cancer Drugs

Hansong Duan
Jiatong Li
Jianfei Ma
Ting Chen
He Zhang
Guanning Shang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1431958

2,073 views
2 citations

Original Research

Published on 31 Jul 2024

Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway

in Pharmacology of Anti-Cancer Drugs

Teng Chen
Pei Zhang
Xiao-Fan Cong
Yuan-Yuan Wang
Shuo Li
Hao Wang
Su-Rong Zhao
Xiao-Jin Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1405521

2,133 views
3 citations

Case Report

Published on 31 Jul 2024

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement

in Pharmacology of Anti-Cancer Drugs

Yang Zheng
Fanfei Zhao
Yaqian Ren
Yaran Xue
Bing Yan
Chun Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1401428

1,409 views
1 citation

Original Research

Published on 31 Jul 2024

MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia

in Pharmacology of Anti-Cancer Drugs

Ying Cui
Xiaoya Shao
Haiping Yang
Jingyi Xin
Yuanyuan Liu
Mingxiao Zhang
Chuanyue Sun
Ge Chen
Guomin Shen
Xueqiong Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1441383

1,956 views
2 citations

Review

Published on 31 Jul 2024

Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment

in Pharmacology of Anti-Cancer Drugs

Yuxuan Tu
Jianbao Gong
Jing Mou
Hongfei Jiang
Haibo Zhao
Jiake Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1434137

3,669 views
9 citations

Systematic Review

Published on 30 Jul 2024

Past and present: a bibliometric study on the treatment of recurrent ovarian cancer

in Pharmacology of Anti-Cancer Drugs

Xiao-yuan Hao
Wen-wei Song
Miao-ling Li
Yi Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1442022

1,998 views
1 citation